Clinical trials
Efficacy and Safety clinical trials
Below are recruiting efficacy and safety clinical trials, each written for real people, not researchers. We’re tracking 2,733 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06728280Recruiting
DTMS for teens with depression: safety and effectiveness
This trial tests if a new type of brain stimulation called DTMS can safely help adolescents with major depression. It may be an option if you have tried other treatments and are looking for a non-medication approach.
Taiyuan, ShanxiAges 11–23 - NCT07309562RecruitingPhase 3
Growth hormone trial for short children born small
This study tests an experimental growth hormone (Inpegsomatropin) to help children born small for gestational age who remain short. If your child meets the specific height, age, and puberty criteria, they may qualify.
BeijingAges 2–11 - NCT07315061RecruitingPhase 2
Testing D-2570 for active psoriatic arthritis
This trial tests an oral medication, D-2570, for people with active psoriatic arthritis. It aims to see if the drug can reduce joint pain and swelling.
Chengdu, SichuanAges 18–70 - NCT07311369RecruitingPhase 2
Testing a new pain tablet after abdominal surgery
This trial tests a new pain tablet (HL-1186) for people having abdominal surgery. It aims to see if the tablet is safe and works well to manage pain after the operation.
Changsha, HunanAges 18–75 - NCT06792682RecruitingPhase 1
Cord blood cells for poor graft function after transplant
This study tests whether umbilical cord blood cells can help patients whose blood counts have dropped again after a stem cell transplant. It may be an option for people who have recovered initially but later develop low blood cell levels.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT07313618RecruitingEarly Phase 1
Gene therapy for children with oculocutaneous albinism type 1
This trial tests a single injection of JWK010 gene therapy for children aged 5 to 12 with OCA1A albinism. The therapy is given into the eye to try to improve vision, and is meant for those who have not had gene therapy before.
Chengdu, SichuanAges 5–12 - NCT07307976Recruiting
Testing a new pain drug for shingles pain
This trial tests a new medicine called crisugabalin to see if it safely reduces shingles pain. It may help if you have moderate to severe pain from a shingles rash that started less than 3 months ago.
BeijingAges 18 years+ - NCT07307170Recruiting
Mirogabalin for shingles pain study
This trial tests a new pain medicine called mirogabalin for people with shingles pain that started within the last 30 days. It aims to see if the drug can safely reduce moderate to severe pain.
BeijingAges 18 years+ - NCT07310316Recruiting
A trial for variceal bleeding in cavernous transformation of portal vein
This study tests a combined procedure to stop bleeding from enlarged veins in the food pipe (varices) in people with a rare condition called cavernous transformation of the portal vein. The treatment involves blocking the bleeding veins and reducing blood flow to the spleen to prevent future bleeding.
Xi'an, ShaanxiAges 18–75 - NCT07307235RecruitingPhase 4
Comparing a new diabetes combination to standard care for type 2 diabetes
This trial tests if a once-daily injectable combination (iGlarLixi) helps control blood sugar better than usual care for people with type 2 diabetes who are already taking diabetes pills. It aims to find a more effective treatment option.
Hefei, AnhuiAges 18 years+ - NCT06838949RecruitingPhase 2
Herombopag for ITP in patients age 60 and older
This trial tests a medication called Herombopag to raise platelet counts in adults aged 60 or older with immune thrombocytopenia (ITP). The goal is to see if it is safe and effective for this age group.
TianjinAges 60 years+ - NCT05930860Recruiting
Endoscopic treatment for certain superficial stomach growths
This trial studies how safe and effective a procedure called endoscopic submucosal dissection (ESD) is for treating certain early, superficial stomach (gastric) growths. It may be an option if your growth fits the endoscopy criteria and you are not a good candidate for stomach surgery.
RomeAges 18 years+ - NCT04666714RecruitingPhase 3
Tested a new medicine to reduce diabetic nerve pain
This Phase 3 study tests Praga formulation to see if it safely reduces nerve pain caused by diabetes. You may qualify if you’re an adult with painful diabetic neuropathy and have certain symptom and pain scores on questionnaires.
Campinas, São PauloAges 18 years+ - NCT07302581Recruiting
Study of dental implants with natural ligament for single tooth replacement
This trial tests a new type of dental implant that includes a ligament (like a natural tooth's shock absorber). It's for people who need to have a single front or side tooth pulled and have healthy gum and bone around the area. The goal is to see if this implant works well and stays healthy over time.
Kōriyama, FukushimaAges 18 years+ - NCT07297329RecruitingPhase 3
Newly diagnosed multiple myeloma trial for transplant-ineligible patients
This trial tests a new drug called SCTC21C combined with standard treatments (bortezomib, lenalidomide, and dexamethasone) for people newly diagnosed with multiple myeloma who cannot have a stem cell transplant. The goal is to see if this combination is safe and works better than current options.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07301749Recruiting
Study of VCFix device for spine fractures
This trial tests a new device called VCFix to treat a single broken vertebra in the mid-to-lower back. It aims to see if the device is safe and effective for relieving pain and restoring spine function.
ChambéryAges 21–85 - NCT07306182RecruitingPhase 2
Testing SGC001 for anterior wall heart attack
This study tests an investigational drug called SGC001 for people having a heart attack affecting the front wall of the heart. The goal is to see if adding this drug to the standard artery-opening procedure helps improve outcomes.
Shanghai, Shanghai MunicipalityAges 18–79 - NCT07303296RecruitingPhase 2
Gene therapy study for vision loss from LHON
This trial tests a gene therapy called GS010 given as an injection into the eye for people with vision loss from LHON. It aims to see if it can help improve vision in both eyes.
ParisAges 15 years+ - NCT07303465RecruitingPhase 2
Testing a new drug for KRAS G12D pancreatic cancer
This trial tests a new experimental drug, RNK08954, for people with advanced pancreatic cancer that has a specific genetic change called KRAS G12D. The goal is to see if the drug is safe and can help shrink or slow the cancer.
NanjingAges 18–75 - NCT07303387RecruitingPhase 2
Valemetostat for solid tumors with SWI/SNF gene changes
This trial tests a new drug, valemetostat, for solid tumors that have specific genetic changes (like loss of SMARCB1, SMARCA4, or ARID1A). It is for people whose cancer has continued to grow despite other treatments. The study will see if valemetostat can help shrink or slow tumors.
Villejuif, Val de MarneAges 18 years+ - NCT07299994Recruiting
Intravenous thrombolysis for specific brain strokes
This trial tests whether a clot-busting drug given through a vein can help people with certain types of deep brain strokes that happen in small arteries. It looks at patients who can be treated within 24 hours of symptoms starting.
Vienna, State of ViennaAges 18 years+ - NCT07297602RecruitingPhase 2
Oral roflumilast for moderate to severe eczema in teens and adults
This study tests an oral medicine called roflumilast to see if it helps treat moderate to severe eczema in people aged 12 and up who haven't used other systemic treatments recently. It's a pilot study to check both safety and how well it works.
Al Mansurah, Dakahlia GovernorateAges 12 years+ - NCT07298239RecruitingEarly Phase 1
CAR-NK cell therapy for advanced prostate cancer
This trial tests a new immune cell therapy (CAR-NK cells) made from a healthy donor's cells. It is designed to attack prostate cancer that has spread and become resistant to hormone therapy, especially if your cancer cells have the PSMA protein.
Beijing, 不限Ages 18 years+ - NCT06849609RecruitingEarly Phase 1
Gene therapy VGN-R13 for ALS safety and tolerability
This study tests a new gene therapy called VGN-R13 for people with ALS. It aims to see if the treatment is safe and tolerable, and if it can slow down the disease. You may be able to join if your ALS symptoms started recently and your lung function is still fairly good.
Wuhan, HubeiAges 18 years+
Hear when a new Efficacy and Safety trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for efficacy and safety?
- Yes. Clin2 currently lists 2,733 recruiting efficacy and safety studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a efficacy and safety trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a efficacy and safety trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.